IGF-1 LR3
Long R3 IGF-1 · LR3
Long-acting IGF-1 analog engineered to resist binding proteins; muscle-growth research compound.
Overview
IGF-1 LR3 (Long R3 IGF-1) is a modified analog of insulin-like growth factor 1, engineered with an arginine substitution at position 3 and an extended N-terminal. That modification sharply reduces binding to IGF-binding proteins, leaving more free, active hormone to stimulate the IGF-1 receptor and drive anabolic and muscle-growth signaling. Compared with native IGF-1, the LR3 variant is more potent and longer-acting. Its estimated half-life is roughly 12 hours with around 60% bioavailability, longer than the native peptide. The honest evidence picture is that human pharmacokinetic data is essentially absent and IGF-1 LR3 is not an approved medication. Most of what is known comes from in vitro potency work, animal studies, and the broader IGF-1 literature.
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 0.5 days
- Bioavailability
- 60%
- Typical dose
- 0.02–0.1 mg
Related compounds
MGF (Mechano Growth Factor)
IGF-1 splice variant produced in response to mechanical load; involved in muscle repair signaling.
PEG-MGF (Pegylated MGF)
Pegylated mechano growth factor with extended half-life versus native MGF; used for recovery research.
IGF-1 DES
Truncated, highly potent IGF-1 variant with very short half-life; site-injection research compound.
Comments
Loading comments…